Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120M
-
Number of holders
-
228
-
Total 13F shares, excl. options
-
127M
-
Shares change
-
+2.06M
-
Total reported value, excl. options
-
$1.78B
-
Value change
-
+$21.6M
-
Put/Call ratio
-
0.53
-
Number of buys
-
123
-
Number of sells
-
-110
-
Price
-
$14.02
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q2 2025
285 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock as of Q2 2025.
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) has 228 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 127M shares
.
Largest 10 shareholders include SUVRETTA CAPITAL MANAGEMENT, LLC (11.5M shares), JENNISON ASSOCIATES LLC (11.1M shares), Rubric Capital Management LP (10.7M shares), Frazier Life Sciences Management, L.P. (9.87M shares), BlackRock, Inc. (8.53M shares), VANGUARD GROUP INC (7.05M shares), Polar Capital Holdings Plc (5.01M shares), STATE STREET CORP (4.53M shares), MORGAN STANLEY (4.31M shares), and GILDER GAGNON HOWE & CO LLC (4.16M shares).
This table shows the top 228 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.